戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ers (eg, rash, pruritus, and urticaria) with insulin glargine.
2 degludec than among those who received basal insulin glargine.
3 afety similar to subcutaneously administered insulin glargine.
4 aryngitis reported in 44 (12%) patients with insulin glargine.
5 e, alogliptin, saxagliptin, sitagliptin, and insulin glargine.
6  with 1.0 mg semaglutide, and five (1%) with insulin glargine.
7  1.0 mg semaglutide, and 26 (7%) assigned to insulin glargine.
8 utide, 360 to 1.0 mg semaglutide, and 360 to insulin glargine.
9 iated with lower risks of hypoglycaemia than insulin glargine.
10  in the group receiving inhaled insulin plus insulin glargine.
11 25, 1.08-1.45; two trials), and neutral with insulin glargine (0.90, 0.77-1.05; one trial).
12  Change in HbA(1c) with inhaled insulin plus insulin glargine (-0.68%, SE 0.077, 95% CI -0.83 to -0.5
13 rgine; estimated treatment difference versus insulin glargine -0.38% (95% CI -0.52 to -0.24) with 0.5
14  degludec plus liraglutide (IDegLira) versus insulin glargine 100 units/mL (IGlar U100) in patients w
15 , 155 (12.4%); liraglutide, 152 (12.0%); and insulin glargine, 150 (11.9%) (P = .56).
16 -2.26 to -1.90) mL/min/1.73 m2 per year; and insulin glargine, -2.02 (95% CI, -2.19 to -1.84) mL/min/
17 rgine; estimated treatment difference versus insulin glargine -4.62 kg (95% CI -5.27 to -3.96) with 0
18 lacebo metformin only, placebo metformin and insulin glargine, active metformin only, or active metfo
19 omly assigned to insulin degludec and 157 to insulin glargine; all were analysed in their respective
20 c) level of 7.1% to 10.5% who were receiving insulin glargine alone or in combination with metformin
21      Although it reduced new-onset diabetes, insulin glargine also increased hypoglycemia and modestl
22         211 patients on inhaled insulin plus insulin glargine and 237 on biaspart insulin were includ
23 nsulin; 107 patients on inhaled insulin plus insulin glargine and 85 on biaspart insulin discontinued
24 ndomized 2 x 2 factorial trial of open-label insulin glargine and placebo-controlled metformin in 500
25        The results of the comparison between insulin glargine and standard care are reported here.
26  cardiovascular outcomes were similar in the insulin-glargine and standard-care groups: 2.94 and 2.85
27 le, double and triple doses of the synthetic insulins glargine and degludec currently used in patient
28 ients were allocated to inhaled insulin plus insulin glargine, and 343 to biaspart insulin; 107 patie
29 e savings associated with a "biosimilar" for insulin glargine approved in 2015.
30 FLD) to receive liraglutide, sitagliptin, or insulin glargine as add-on to metformin.
31  efficacy and safety of insulin degludec and insulin glargine, both administered once daily with meal
32 -1 receptor agonist dulaglutide with that of insulin glargine, both combined with prandial insulin li
33 dial insulin as an additional treatment with insulin glargine demonstrated reductions in HbA1c and bo
34 07), respectively, with insulin degludec and insulin glargine (estimated treatment difference -0.01%
35 us a weight gain of 1.15 kg (0.70-1.61) with insulin glargine; estimated treatment difference versus
36  respectively, versus 0.83% (0.73-0.93) with insulin glargine; estimated treatment difference versus
37 pe 2 diabetes were randomized to 3 months of insulin glargine followed by 9 months of metformin, or 1
38 ith T2DM were randomized to the EXE group or insulin glargine (GLAR) control group for a total treatm
39 comparison with another long-acting insulin, insulin glargine (GLAR), DET led to more prolonged incre
40 t group in participants randomly assigned to insulin glargine, glimepiride, liraglutide, or sitaglipt
41                                  Addition of insulin glargine, glimepiride, liraglutide, or sitaglipt
42 ed to study medication) and two (<1%) in the insulin glargine group (both cardiovascular death).
43     Median weight increased by 1.6 kg in the insulin-glargine group and fell by 0.5 kg in the standar
44 re) were similar in the insulin degludec and insulin glargine groups (42.54 vs 40.18 episodes per pat
45 e) were similar for the insulin degludec and insulin glargine groups.
46 plasma glucose levels for more than 6 years, insulin glargine had a neutral effect on cardiovascular
47 N-3, exenatide once weekly was compared with insulin glargine (henceforth, glargine) as first injecta
48  three times a week (IDeg 3TW) to once-daily insulin glargine (IGlar OD).
49 own to provide similar treatment outcomes to insulin glargine in a phase 2a clinical trial.
50 nd GLP-1 receptor agonist tirzepatide versus insulin glargine in adults with type 2 diabetes and high
51 and safety of insulin degludec compared with insulin glargine in patients with type 2 diabetes mellit
52 logue in clinical development, compared with insulin glargine in patients with type 2 diabetes who we
53 us glycemic control comparable to once-daily insulin glargine in type 2 diabetes patients.
54 hort) vs insulin lispro, both in addition to insulin glargine, in HbA1c change from baseline at week
55                                              Insulin glargine, insulin detemir, and NPH insulin.
56 placebo, or active comparators (glimepiride, insulin glargine, insulin lispro, liraglutide, pioglitaz
57                  Conclusion Long-term use of insulin glargine is associated with an increased risk of
58 ous injection in diabetic rats, insulin- and insulin glargine-loaded nanoparticles of diverse morphol
59 eneficiaries 65 years or older who initiated insulin glargine (n = 407 018), insulin detemir (n = 141
60 1984 and 31 January 2019: metformin (n = 8), insulin glargine (n = 6), short-acting insulin (n = 2),
61 in A Study of Tirzepatide Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2
62 n glulisine) and basal insulin (for example, insulin glargine or insulin detemir), the analogues simu
63 acids or placebo daily and to receive either insulin glargine or standard care.
64 nosphere inhaled insulin powder plus bedtime insulin glargine; or twice daily premixed biaspart insul
65 with 1.0 mg semaglutide versus 38 (11%) with insulin glargine (p=0.0021 and p=0.0202 for 0.5 mg and 1
66 s in total US sales and net prices for all 3 insulin glargine products from quarter 1 of 2010 through
67 =0.0202 for 0.5 mg and 1.0 mg semaglutide vs insulin glargine, respectively).
68 ilability, in comparison to free insulin and insulin glargine, respectively.
69 daily administration of marketed long-acting insulin, glargine, resulted in fluctuating blood glucose
70                               Bedtime use of insulin glargine results in fewer episodes of nighttime
71                INTERPRETATION: Compared with insulin glargine, semaglutide resulted in greater reduct
72 fixed dose-escalation regimen) or once-daily insulin glargine (starting dose 10 IU per day, then titr
73 hypoglycaemic events on inhaled insulin plus insulin glargine than on biaspart insulin.
74 ding of short-acting insulin and long-acting insulin glargine to nanoparticles resulted in extended h
75 ontrolled type 2 diabetes who were receiving insulin glargine treatment.
76         The randomly assigned therapies were insulin glargine U-100 (hereafter, glargine), glimepirid
77 We randomly assigned participants to receive insulin glargine U-100 (hereafter, glargine), the sulfon
78 e either insulin degludec (3818 patients) or insulin glargine U100 (3819 patients) once daily between
79  once-weekly icodec compared with once-daily insulin glargine U100 (glargine U100) in individuals wit
80 o receive once-weekly efsitora or once-daily insulin glargine U100 (glargine).
81 lin degludec vs 2.4% (95% CI, 1.1%-3.7%) for insulin glargine U100 (McNemar P = .35; risk difference,
82 eive once-daily insulin degludec followed by insulin glargine U100 (n = 249) or to receive insulin gl
83 eive once-daily insulin degludec followed by insulin glargine U100 (n = 361) or to receive insulin gl
84 nsulin glargine U100 (n = 249) or to receive insulin glargine U100 followed by insulin degludec (n =
85 nsulin glargine U100 (n = 361) or to receive insulin glargine U100 followed by insulin degludec (n =
86 patients in the insulin degludec than in the insulin glargine U100 group experienced severe hypoglyce
87  group vs 2462.7 episodes per 100 PYE in the insulin glargine U100 group for a rate ratio (RR) of 0.8
88 c group vs 428.6 episodes per 100 PYE in the insulin glargine U100 group, for an RR of 0.64 (95% CI,
89 safety of once-weekly efsitora compared with insulin glargine U100 in adults with type 2 diabetes tre
90 y insulin icodec as compared with once-daily insulin glargine U100 in patients who had not previously
91 afety profile similar to those of once-daily insulin glargine U100 in patients with type 2 diabetes.
92 h a lower rate of hypoglycemia compared with insulin glargine U100 in patients with type 2 diabetes.
93 sulin degludec is noninferior or superior to insulin glargine U100 in reducing the rate of symptomati
94 32 weeks' treatment with insulin degludec vs insulin glargine U100 resulted in a reduced rate of over
95 32 weeks' treatment with insulin degludec vs insulin glargine U100 resulted in a reduced rate of over
96 tomatic hypoglycemia for insulin degludec vs insulin glargine U100 were 185.6 vs 265.4 episodes per 1
97 omatic hypoglycemia with insulin degludec vs insulin glargine U100 were 55.2 vs 93.6 episodes/100 PYE
98 tomatic hypoglycemia for insulin degludec vs insulin glargine U100 were also seen for the full treatm
99 c with app or OD analogue (insulin degludec, insulin glargine U100, or insulin glargine U300).
100 e-weekly insulin icodec than with once-daily insulin glargine U100.
101 ive once-weekly insulin icodec or once-daily insulin glargine U100.
102 (insulin degludec, insulin glargine U100, or insulin glargine U300).
103                   Compared with NPH insulin, insulin glargine was associated with an increased risk o
104                                              Insulin glargine was the most frequently used insulin fr
105 ose tolerance, or type 2 diabetes to receive insulin glargine (with a target fasting blood glucose le
106 tive metformin only, or active metformin and insulin glargine) with dose titration targeting fasting
107  allocation sequence, to insulin degludec or insulin glargine without stratification by use of a cent

 
Page Top